The successful scientist will work with colleagues throughout BMS to establish assays using immunohistochemistry, multiplex staining/imaging, in situ nucleic acid hybridization, and digital pathology. The scientist will be directly responsible for the design, development, execution, and analysis of discovery and translational tissue-based biomarker assays to interrogate target prevalence, target engagement, mechanisms of action, pharmacokinetics, pharmacodynamics, and prediction of treatment response. The position entails working on projects independently and in multi-disciplinary teams consisting of pathologists, lab scientists, data scientists, and clinical biomarker scientists. The IHC scientist will develop tissue-based assays for internal or external use with accountability for assays transferred to partner labs and contract research organizations (CROs). The scientist will also be responsible for working independently and with digital pathology colleagues to build and assess image analysis algorithms and workflows. The successful scientist must have strong technical experience in IHC assay development using several platforms and techniques and a working knowledge of histology/morphology/pathology interpretation relevant to assay development. The scientist must show strong communication and organizational skills, the ability to work collaboratively with other team members, adaptability to regulated work environments, and the flexibility to accommodate changing business needs.